On July 25, 2022, the US Food and Drug Administration (FDA) approved Azilsartan Medoxomil tablets, a generic hypertension drug developed by Lupin is used to treat hypertension or high blood pressure.
The product is a generic equivalent of Edarbi tablets, 40 and 80 mg, developed by Azurity Pharmaceuticals, Inc., and the drug is mainly used to decrease high blood pressure. The Azilsartan Medoxomil tablets will be manufactured at the facility of Lupin based in Nagpur, India.
According to Lupin, Azilsartan Medoxomil tablets had an estimated annual sale of 101 million dollars in the United States of America. Lupin is a Mumbai-based multinational pharmaceutical company led by innovation. The company mainly develops and commercializes a wide range of generic and branded formulations, APIs, and biotechnology products in more than 100 markets in the United States of America, South Africa, India, and across Europe, the Middle East, Latin America, and Asia-Pacific regions.
The income operations of the company have been increased by 2.8 percent year on year during the fourth quarter, and the shares of Lupin have been dropped by 1.01 percent to settle at 632.80 rupees.
